Health ❯ Pharmaceuticals ❯ Drug Development ❯ Clinical Trials

Semaglutide

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Novo Nordisk Launches Wegovy Weight-Loss Drug in India